FDA Underlines Disapproval Of Drug-Supplement Combos In Letter To P&G
This article was originally published in The Tan Sheet
Executive Summary
FDA notes once again that combination OTC drug and dietary supplement products are unapproved new drugs with a warning letter sent Oct. 29 to Procter & Gamble about Vicks DayQuil Plus Vitamin C and VicksNyQuil Plus Vitamin C
You may also be interested in...
OTC Firms Should Improve Monograph Compliance, Registration – CDER
CDER recommends the OTC industry ensure product innovations comply with monographs or have FDA approval prior to marketing. Umbrella-branding and facility registration rank high for the drug center in 2013.
OTC Firms Should Improve Monograph Compliance, Registration – CDER
CDER recommends the OTC industry ensure product innovations comply with monographs or have FDA approval prior to marketing. Umbrella-branding and facility registration rank high for the drug center in 2013.
FDA Warns Matrixx On Combination Supplement/Drug Products
Matrixx Initiatives’ troubled history with FDA continues with a warning two of its products are unapproved new drugs because they combine supplements with OTC drugs.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: